Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M Kuderer, MD †
Toni K Choueiri, MD †
Dimpy P Shah, PhD †
Yu Shyr, PhD †
Samuel M Rubinstein, MD
Donna R Rivera, PharmD
et al.
Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31187-9
Summary
Background
Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.
Methods
In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.
